DSM Sinochem wins patent infringement ruling against Sinopharm Weiqida

By Flora Southey contact

- Last updated on GMT


Related tags: Patent application

The High Court of Delhi, India, has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical for patent infringement of DSM Sinochem Pharmaceuticals’ enzyme-based antibiotic production IP.

Indian Patent Number 247,301 is owned by DSM Sinochem Pharmaceuticals (DSP), and relates to enzymatic processes used to manufacture amoxicillin trihydrate.

“DSP tested Weiqida’s amoxicillin trihydrate samples to reverse engineer the manufacturing process likely used in their production,” ​DSM director of branding and communication Alice Beijersbergen told in-PharmaTechnologist.

“Weiqida failed to substantively defend against our claims of infringement or provide evidence of the use of an alternative process,” ​she said.

The ruling prevents the manufacture, use, importation, offering of sale and sale of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient (API) in India.

The injunction also prohibits these activities for any drug product that utilises the API.

“By restricting the flow of the Weiqida API through India, we disrupt the supply chain of infringing API,” ​said Beijersbergen.

Enzymes for antibiotics

According to DSP, its patented technologies have green, enzymatic routes for the production of amoxicillin and other antibiotics.

“DSP is continuing to invest in this sustainable technology, so it is important that our investment is protected from infringement, especially in major pharmaceutical markets like India,” ​said Beijersbergen. 

“DSP is open to licensing its technology to third parties, but it cannot tolerate infringement,” ​she said.

DSP has also filed patent litigation​ against Weiqida in the Netherlands over the European equivalent of this patent.

Related news

Show more

Related products

show more

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Related suppliers

Follow us


View more